問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Urology

Division of Nuclear Medicine

Division of Hematology & Oncology

更新時間：2023-09-19

蒲永孝Pu, Yeong-Shiau
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 10 個月

  • uroassistant2014@gmail.com

Recruiting Trial

62Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蒲永孝

List

135Cases

2025-04-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2019-05-19 - 2027-01-25

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2010-01-01 - 2013-07-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2009-05-01 - 2013-01-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2015-01-01 - 2018-12-31

Phase III

A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI−PD-L1 ANTIBODY) COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY

  • Condition/Disease

    Urothelial Bladder Cancer

  • Test Drug

    TECENTRIQ® (Atezolizumab)

Participate Sites
4Sites

Terminated4Sites

2017-02-01 - 2023-02-28

Phase III

A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy

  • Condition/Disease

    Renal Cell Carcinoma

  • Test Drug

    Atezolizumab

Participate Sites
6Sites

Terminated5Sites

莊正鏗
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2015-04-10 - 2019-06-30

Phase III

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF MPDL3280A (AntiPD-L1 ANTIBODY) IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCINOMA

  • Condition/Disease

    UNTREATED ADVANCED RENAL CELL CARCINOMA

  • Test Drug

    Atezolizumab

Participate Sites
3Sites

Terminated3Sites

莊正鏗
Linkou Chang Gung Medical Foundation

Division of General Surgery

2007-02-01 - 2010-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2007-11-01 - 2010-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2011-03-15 - 2017-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

1 7 8 9 10 11 14
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB